JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

NASDAQ:JAZZ • IE00B4Q5ZN47

167.61 USD
-0.37 (-0.22%)
Last: Feb 18, 2026, 11:07 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, JAZZ scores 4 out of 10 in our fundamental rating. JAZZ was compared to 191 industry peers in the Pharmaceuticals industry. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health. JAZZ is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • JAZZ had positive earnings in the past year.
  • In the past year JAZZ had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
  • Each year in the past 5 years JAZZ had a positive operating cash flow.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • JAZZ has a better Return On Assets (-3.24%) than 74.35% of its industry peers.
  • With a decent Return On Equity value of -9.31%, JAZZ is doing good in the industry, outperforming 74.87% of the companies in the same industry.
  • The Return On Invested Capital of JAZZ (3.95%) is better than 82.72% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.64%.
  • The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROIC 3.95%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

  • In the last couple of years the Profit Margin of JAZZ has declined.
  • JAZZ has a better Operating Margin (10.92%) than 83.77% of its industry peers.
  • In the last couple of years the Operating Margin of JAZZ has declined.
  • Looking at the Gross Margin, with a value of 88.49%, JAZZ belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
  • JAZZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 88.49%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
  • Compared to 1 year ago, JAZZ has less shares outstanding
  • The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
  • Compared to 1 year ago, JAZZ has a worse debt to assets ratio.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 1.54, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of JAZZ (1.54) is comparable to the rest of the industry.
  • The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.33, JAZZ belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
  • JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of JAZZ (1.09) is worse than 74.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Altman-Z 1.54
ROIC/WACC0.52
WACC7.64%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

  • JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of JAZZ (1.65) is worse than 68.06% of its industry peers.
  • A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.44, JAZZ is not doing good in the industry: 63.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.44
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.39%.
  • JAZZ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.47% yearly.
  • The Revenue has been growing slightly by 4.14% in the past year.
  • Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%

3.2 Future

  • Based on estimates for the next years, JAZZ will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.62% on average per year.
  • Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 7.50% on average per year.
EPS Next Y-60.74%
EPS Next 2Y4.5%
EPS Next 3Y6.57%
EPS Next 5Y8.62%
Revenue Next Year4.8%
Revenue Next 2Y5.63%
Revenue Next 3Y6.42%
Revenue Next 5Y7.5%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 20.54, which indicates a rather expensive current valuation of JAZZ.
  • Compared to the rest of the industry, the Price/Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 81.68% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.16, JAZZ is valued a bit cheaper.
  • The Price/Forward Earnings ratio is 7.24, which indicates a rather cheap valuation of JAZZ.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 93.19% of the companies listed in the same industry.
  • JAZZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.10.
Industry RankSector Rank
PE 20.54
Fwd PE 7.24
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 87.96% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaper than 93.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.22
EV/EBITDA 11.24
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

  • JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.76
EPS Next 2Y4.5%
EPS Next 3Y6.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (2/18/2026, 11:07:31 AM)

167.61

-0.37 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)02-24
Inst Owners104.02%
Inst Owner Change-0.8%
Ins Owners2.48%
Ins Owner Change-0.22%
Market Cap10.19B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts85.22
Price Target221.83 (32.35%)
Short Float %9.62%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.93%
PT rev (3m)14.73%
EPS NQ rev (1m)2.08%
EPS NQ rev (3m)5.88%
EPS NY rev (1m)1.18%
EPS NY rev (3m)54.77%
Revenue NQ rev (1m)1.02%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.37%
Valuation
Industry RankSector Rank
PE 20.54
Fwd PE 7.24
P/S 2.45
P/FCF 8.22
P/OCF 7.32
P/B 2.57
P/tB N/A
EV/EBITDA 11.24
EPS(TTM)8.16
EY4.87%
EPS(NY)23.14
Fwd EY13.8%
FCF(TTM)20.39
FCFY12.16%
OCF(TTM)22.9
OCFY13.66%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.76
Graham Number109.37
Profitability
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROCE 5%
ROIC 3.95%
ROICexc 5.1%
ROICexgc 55.75%
OM 10.92%
PM (TTM) N/A
GM 88.49%
FCFM 29.8%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Debt/EBITDA 3.8
Cap/Depr 22.29%
Cap/Sales 3.68%
Interest Coverage 250
Cash Conversion 122.16%
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.44
Altman-Z 1.54
F-Score5
WACC7.64%
ROIC/WACC0.52
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-60.74%
EPS Next 2Y4.5%
EPS Next 3Y6.57%
EPS Next 5Y8.62%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.8%
Revenue Next 2Y5.63%
Revenue Next 3Y6.42%
Revenue Next 5Y7.5%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.7%
EBIT Next 3Y5.83%
EBIT Next 5Y6.52%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.


Can you provide the financial health for JAZZ stock?

The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -60.74% in the next year.